December 14, 2005

Ventracor Limited (ASX: VCR) moved a step closer to completing enrolment in its CE Mark Trial announcing the successful implant of its left ventricular assist device (LVAD), the VentrAssist, at Norway's Rikshopitalet University Hospital.

Ventracor Limited Chief Executive Officer Colin Sutton PhD said: "Clinical knowledge and experience in surgical procedures and patient management is growing rapidly.

"Recent implants in Norway, Perth, Sydney, Auckland and Brisbane bring enrolments in the CE Mark Trial closer to completion.

"We expect there will be additional implants in the coming weeks and are on track to complete recruitment in the CE Mark Trial before the end of the first quarter 2006."

Dr Sutton added Ventracor had developed training programs and added field support which would allow the company to carefully expand the number of European hospitals implanting the VentrAssist LVAD.

Ventracor's CE Mark Trial is aimed at obtaining approval to sell the VentrAssistTM in the major market of Europe.

Dr Sutton added Ventracor continued to focus on achieving key milestones.
About Ventracor
Ventracor is a global medical device company that has developed a blood pump, the VentrAssistTM left ventricular assist system (LVAS) for patients in cardiac failure. The company hopes to bring the VentrAssistTM to the global market in record time, and expects to obtain a significant share of the huge potential market.

For further information, please contact:
Andrew Geddes
Manager, Investor Relations
Ventracor Limited

Research Australia

Related Added Field Support Articles from Brightsurf:

Field courses boost student success, support STEM diversity efforts, study reveals
The challenge of diversifying STEM fields may get a boost from the results of a new study that show field courses help build self-confidence among students -- especially those from underrepresented groups.

O-FIB: Far-field-induced near-field breakdown for direct nanowriting in an atmospheric environment
Nanoscale texturing, drilling, cutting and spatial sculpturing require not only high accuracy, but also the capability of manufacturing in the atmospheric environment.

Pembrolizumab in metastatic NSCLC: Now added benefit for subpopulations
After a methodological uncertainty has been resolved, the analyses on overall survival are now usable.

No evidence of added benefit for most new drugs, say researchers
More than half of new drugs entering the German healthcare system have not been shown to add benefit, argue researchers in The BMJ today.

Melanoma: dabrafenib and trametinib have added benefit
This combination showed advantages in survival and recurrence. An added benefit was not proven for another combination used in advanced disease.

NASA added up Typhoon Prapiroon's rainfall
Tropical cyclones can generate a tremendous amount of rainfall, and NASA's IMERG program utilizes a variety of data to create rainfall maps.

American toddlers consume too much added sugar
A new study suggests children in the US begin consuming added sugar at a very young age and that many toddlers' sugar intake exceeds the maximum amount recommended for adults.

Bronchial carcinoma: Added benefit of crizotinib not proven
The dossier contains no data or no suitable data on ROS1-positive, advanced non-small cell lung cancer.

Seven substances added to 14th Report on Carcinogens
Today's release of the US Department of Health and Human Services 14th Report on Carcinogens includes seven newly reviewed substances, bringing the cumulative total to 248 listings.

New mobile robot to support agri-tech experiments in the field
A new agricultural robot with technology which has the potential to change the landscape of arable farming is being field-tested at the University of Lincoln, UK.

Read More: Added Field Support News and Added Field Support Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to